Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05825781
Other study ID # PERT-1/12102020
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date July 20, 2023
Est. completion date June 2024

Study information

Verified date February 2024
Source Mabscale, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PERT-1/12102020 is a double-blind randomized single-center clinical trial comparing pharmacokinetics, immunogenicity and safety profiles of Pertuzumab (manufactured by Mabscale, LLC) compared to Perjeta® in healthy men. The purpose of the study is to demonstrate equivalence of pharmacokinetics, immunogenicity and safety of Pertuzumab (manufactured by Mabscale, LLC) to Perjeta®.


Description:

Pertuzumab is a recombinant humanized monoclonal antibody currently being developed by Mabscale LLC, as a proposed biosimilar to Perjeta®, which is approved as treatment in patients with metastatic breast cancer in combination with trastuzumab and docetaxel and in patients with non-metastatic breast cancer in combination with trastuzumab and chemotherapy. This randomized equivalence study is designed to meet the regulatory requirement for approval of a biosimilar product.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 114
Est. completion date June 2024
Est. primary completion date January 22, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Healthy Volunteers, Men, 18 to 45 years old. - Body mass index 18,5 - 30,0 kg/m2. - Availability of written informed consent of the volunteer to participate in the study in accordance with applicable law. - Volunteers should behave adequately, coherent speech should be observed. - Volunteer consent to use an adequate method of contraception (barrier methods of contraception in combination with one of the following: non-hormonal intrauterine device; condom with intravaginal spermicide; cervical caps with spermicide; diaphragm with spermicide in the sexual partner) during the entire period of participation in the study and at least 6 months after the use of the study drug/comparator drug. - The verified diagnosis is "healthy": the absence of pathology from the gastrointestinal tract, liver, kidneys, cardiovascular and bronchopulmonary systems, central nervous system (preliminary standard clinical, laboratory and instrumental studies did not reveal the presence of any diseases). - Negative blood tests for HIV, syphilis and hepatitis (HBsAg and anti-HCV). - LVEF = 60% according to ECHO-CG. - Negative urine test for drug and drug abuse. - Negative breath alcohol test. Exclusion Criteria: 1. Aggravated allergic anamnesis. 2. Hypersensitivity to pertuzumab and / or other substances that are part of the study drug. 3. Any vaccination up to 30 days before the expected date of administration of the drug according to medical history. 4. Drug intolerance. 5. Known intolerance to monoclonal antibody drugs (mouse, chimeric, humanized, human) according to medical history. 6. The results of laboratory analyzes provided for by the protocol are outside the established normative indicators of the investigator site. 7. Oncological diseases according to medical history. 8. Acute and chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys, hematopoietic, immune systems, mental illness. 9. More than 4 episodes of respiratory infections in the last 6 months prior to screening. 10. Surgical interventions on the gastrointestinal tract (with the exception of appendectomy). 11. Acute infectious diseases less than 4 weeks prior to study entry. 12. Taking drugs that have a pronounced effect on hemodynamics, liver function, etc. (barbiturates, omeprazole, cimetidine, etc.) less than 2 months before the start of this study. 13. Regular drug intake less than 2 weeks before the start of the study. 14. Systolic blood pressure less than 100 mm Hg. Art. or above 130 mm Hg. Art.; diastolic blood pressure less than 60 mm Hg. Art. or above 90 mm Hg. Art.; Heart rate less than 60 bpm or more than 90 bpm; respiratory rate less than 12 and more than 20 per minute 15. Donation of blood (450 ml of blood or more) less than 3 months before the start of the study. 16. Participation in clinical drug trials less than 3 months before the start of this study. 17. Taking more than 10 units of alcohol per week (where each unit is equal to 50 ml of strong alcoholic beverages or 500 ml of beer) or anamnestic information about alcoholism, drug addiction, drug abuse. 18. Smoking more than 10 cigarettes a day. 19. Any reason that, in the opinion of the investigator, would prevent a volunteer from participating in the study. 20. Mental, physical and other reasons that do not allow the subject adequately assess his behavior and correctly fulfill the conditions of the research protocol. 21. Special diet (eg vegetarian, vegan) or lifestyle (including night work and extreme physical activity such as heavy lifting) that may interfere with the study. 22. Volunteers who are expected to have problems with placing venous catheters or performing veinpuncture. 23. Depression according to medical history. 24. Insomnia according to medical history. 25. Inability to follow the schedule of study visits by a volunteer.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pertuzumab
i.v.
Perjeta®
i.v.

Locations

Country Name City State
Russian Federation Central Clinical Hospital "RZD-Medicina" Moscow

Sponsors (1)

Lead Sponsor Collaborator
Mabscale, LLC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Concentration of pertuzumab in serum of subjects Baseline up to 100 days after study drug administration
Secondary Rate of subjects with antibodies against pertuzumab in serum Baseline up to 100 days after study drug administration
See also
  Status Clinical Trial Phase
Completed NCT02575209 - Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects N/A
Completed NCT00900107 - Time-Dependent Mobilization of Circulating Progenitor Cells During Strenuous Exercise in Healthy Individuals N/A
Completed NCT02517775 - Effects of Cranberry Consumption in Vascular Function in Healthy Individuals N/A
Active, not recruiting NCT03298373 - 28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men Phase 1
Completed NCT03339167 - Metabolic Availability of Lysine From Millet in Adult Men N/A
Completed NCT01710280 - Palmitic Acid in the Sn-2 Position of Triacylglycerols and Postprandial Lipemia N/A
Completed NCT01130948 - Sleep, Breathing and Psychomotor Performance at Altitude: A Physiologic Study in Healthy Subjects N/A
Completed NCT01382069 - Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men Phase 1
Recruiting NCT05523674 - Effects of Warm-up Intensity and Blood Flow Restriction N/A
Not yet recruiting NCT05865574 - A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection Phase 1
Completed NCT01293591 - Garlic Intake And Biomarkers Of Cancer Risk N/A
Completed NCT01296997 - Calcium Phosphate and Incretins N/A
Completed NCT00935662 - A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses Phase 1
Completed NCT01221558 - Effects of Lycopene on Oxidative Stress and Markers of Endothelial Function Healthy Men Phase 3
Completed NCT02994602 - Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males Phase 1
Completed NCT02365987 - The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety N/A
Completed NCT02072278 - Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects Phase 1
Completed NCT02093169 - D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound Phase 1
Completed NCT03411005 - Metabolic Availability of Lysine From Sorghum in Adult Men N/A
Recruiting NCT02927210 - Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015) Phase 1